Brought to you by 
Specialised Therapeutics to market Yondelis for PharmaMar
22 Oct 2019
Executive Summary
PharmaMar SA granted Specialised Therapeutics Asia Pte. Ltd. (STA) exclusive rights to market the sarcoma therapy Yondelis (trabectedin) in Australia, New Zealand, and Southeast Asia. (Former Yondelis licensee Janssen will continue to distribute the drug in Singapore, Malaysia and Brunei until STA formally takes over marketing authorization.)
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Specialised Therapeutics to market Yondelis for PharmaMar
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice